ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma Published: Oct 29, 2021 | Tags: ADC, EMA, MAA, Zynlonta, R/R Diffuse Large B-Cell Lymphoma […]readmore
Tags : Angion
Shots: The P-III trial evaluates ANG-3777 (qd for 3days) vs PBO in a ratio (1:1) in 253 patients with kidney transplants who were at risk for developing DGF The trial […]readmore
BMS Reports the US FDA’s Acceptance of Opdivo’s sBLA for Priority Review to Treat Muscle Invasive Urothelial Carcinoma Published: Apr 30, 2021 | Tags: BMS, US, FDA, Opdivo, sBLA, Priority […]readmore
Shots: The companies have completed the enrolment in P-II AKI-002-15 study evaluating the safety and efficacy of ANG-3777 (2.0 mg/kg, IV) vs PBO over 4 days in patients with CSA-AKI […]readmore
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected […]readmore
Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it The outbreak of the respiratory disease was first detected […]readmore
1. LEO Reports the US FDA’s Acceptance of BLA for Tralokinumab to Treat Adults with Moderate to Severe Atopic Dermatitis Published Date: Jul 10, 2020 | Tags: LEO, Reports, US, […]readmore
Shots: The P-II POC study assess safety and efficacy of ANG-3777 (2.0 mg/kg, IV) + SOC vs PBO + SOC in ~100 patients in a ratio (1:1) hospitalized with confirmed […]readmore